Associate Director
Oruka Therapeutics
Associate Director
Oruka Therapeutics
Clinical-stage antibody therapies for psoriasis
About Us:
Oruka Therapeutics (Nasdaq: ORKA) is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com
As we build our core team, we're seeking top talent in different functional areas who are not just looking for a job, but an opportunity to be part of something bigger. Someone who is passionate about making a difference and eager to contribute to establishing an engaged, inclusive, and positive company culture.
Job Title: AssociateDirector, Formulation Development, Tech Ops (Biologics)
Location: Remote OR Hybrid 3 days/week if located near office in either Waltham, MA or Menlo Park, CA will be required.
Role Overview:
The Associate Director of Formulation Development will provide scientific and strategic leadership for early- and late-stage formulation development activities supporting phase-appropriate formulations of biologic drug products, with a focus on monoclonal antibodies, bispecific formats, and co-formulations. This role will lead formulation development and container closure selection, and partner with the Drug Product team to support process development studies across early- and late-stage development. The position will support BLA/MAA submissions, formulation changes, and commercial readiness, while partnering closely with CMC, Quality, Regulatory Affairs, and external partners.
The ideal candidate is a hands-on leader with deep expertise in formulation development for complex biologics, spanning early through late-stage development, with a focus on commercial readiness. This role is highly visible within the CMC team and a pivotal addition to our growing organization where you will play an integral role in supporting multiple programs’ formulation activities for clinical trials and preparing for commercialization across the US, Canada, and EU.
The ideal candidate is a hands-on leader with deep expertise in formulation development for complex biologics, spanning early through late-stage development, with a focus on commercial readiness. This role is highly visible within the CMC team and a pivotal addition to our growing organization where you will play an integral role in supporting multiple programs’ formulation activities for clinical trials and preparing for commercialization across the US, Canada, and EU.
Key Responsibilities:
Qualifications:
Compensation:
We're looking forward to hearing how you can contribute to our team and mission. Join us in shaping the future of our company and making a real impact every day.
What We Offer:
Salary Range for the Role 182000 - 208000 USD
Clinical-stage antibody therapies for psoriasis
Oruka Therapeutics develops antibody-based therapies for chronic skin diseases, focusing on plaque psoriasis and psoriatic arthritis. Its monoclonal antibodies, discovered and engineered by Paragon Therapeutics, are designed for longer dosing intervals to improve patient convenience. ORKA-001 targets IL-23p19 with an extended half-life that could allow dosing once or twice a year, while ORKA-002 targets IL-17A/F with dosing two to three times per year; both are in early-stage trials with Phase 2 planned for 2025–2026. The company aims to deliver higher skin clearance and durable remission to the large patient pool, pursuing commercialization after advancing through clinical trials; it entered public markets via a 2024 reverse merger with ARCA biopharma and raised over $475 million to fund operations through 2027.
Explore more opportunities at Oruka Therapeutics